GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Net Income Including Noncontrolling Interests

Biosergen AB (FRA:8N1) Net Income Including Noncontrolling Interests : €-1.69 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Biosergen AB's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was €-0.47 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was €-1.69 Mil.

Biosergen AB Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Biosergen AB's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Net Income Including Noncontrolling Interests Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
-0.66 -3.34 -3.10 -2.42 -1.67

Biosergen AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.51 -0.38 -0.33 -0.47

Biosergen AB Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosergen AB Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosergen AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XSAT:ABERA XSAT:BIOWKS OSTO:KAN XSAT:DEX OSTO:ALZ OSTO:NICA OSTO:PILA NGM:GTAB B OSTO:SPAGO OSTO:ISOFOL VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
BIOSGN:Sweden
Address
Fogdevreten 2, Solna, SWE, 17165
Website
https://www.biosergen.net
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.

Biosergen AB Headlines

No Headlines